Want to see ZLAB full AI Analyst Report?
Top Page
Zai Lab
(NASDAQ:ZLAB)
Select Model
Select Model
Rating:52Neutral
Price Target:
$18.50
▼(-3.75% Downside)
Action:Reiterated
Date:08/07/26
The score reflects a tension between near-term financial strain and improving strategic momentum. Financial performance is pressured by large operating losses, ongoing cash burn, and a sharp TTM revenue contraction, which are the biggest drags. Offsetting this, the earnings call was notably positive on commercial profitability, cash runway, and a dense set of clinical and commercial milestones. Technicals remain bearish, and valuation is hard to anchor with negative earnings.
Positive Factors
Strong Cash Position
A $717.5M cash balance gives Zai Lab multi-quarter runway to fund global registrational trials and commercialization without immediate capital raises. This liquidity supports continued R&D investment and operational stability while pivotal readouts and launches progress over the next 2–6 months.
Negative Factors
Persistent Negative Cash Flow
Despite a strong cash balance, persistent TTM operating and free cash flow deficits mean the company is still burning cash. Continued negative cash generation raises the probability of future financing, dilution, or spending cuts if commercial gains or trial milestones don't materialize to reverse the trend.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Cash Position
A $717.5M cash balance gives Zai Lab multi-quarter runway to fund global registrational trials and commercialization without immediate capital raises. This liquidity supports continued R&D investment and operational stability while pivotal readouts and launches progress over the next 2–6 months.
Read all positive factors
Zai Lab (ZLAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.91B
Dividend YieldN/A
Average Volume (3M)835.97K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth5.13%
EPS Growth17.00%
CountryUS
Employees1,784
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.76
Shares Outstanding113,782,810
10 Day Avg. Volume711,769
30 Day Avg. Volume835,967
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)2.70
Price to Sales (P/S)4.20
P/FCF Ratio-11.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.65Price Target Upside69.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$432.67M
Zai Lab Business Overview & Revenue Model
Company Description
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmu...
How the Company Makes Money
Zai Lab makes money primarily by commercializing prescription medicines and recognizing product sales revenue from those products in its covered markets (primarily Greater China). A significant part of its business model is to in-license or collab...
Zai Lab Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call emphasized multiple near-term and medium-term positive catalysts: sequential revenue growth (11% QoQ to $105.8M), a commercially profitable business, a strong cash balance ($717.5M), rapid advancement of Zoci into global registrational trials with notable efficacy signals (38.2% ORR vs ~18% comparator in neuroendocrine carcinoma), and a busy pipeline with several upcoming data milestones (ESMO presentation, ZL-1503 healthy volunteer data H2 2026, ZL-6201 initial data H1 2027, ZL-1311 IND by year-end). Management also highlighted disciplined spending and productivity efforts. Counterbalancing these positives are supply constraints, near-term revenue timing issues related to NRDL and formulation transitions, increasing competition in the IL-13/IL-31 AD space, clinical safety/combination risks, and some ambiguity around the timing of profitability and key readouts. Overall, the positives — particularly pipeline momentum, commercial profitability, and cash runway — outweigh the operational and timing uncertainties.Positive Updates
Sequential Revenue Growth and Commercial Profitability
Net product revenue grew 11% sequentially to $105.8 million in Q2 2026, and the company stated its commercial business remained commercially profitable.
Negative Updates
Supply Constraints and Near-Term Revenue Timing Issues
XACDURO is experiencing supply constraints. Management noted reported revenue in the second half of 2026 may not fully reflect underlying demand because of NRDL timing and the planned transition of VYVGART from IV to subcutaneous delivery.
Read all updates
Q2-2026 Updates
Positive
Negative
Sequential Revenue Growth and Commercial Profitability
Net product revenue grew 11% sequentially to $105.8 million in Q2 2026, and the company stated its commercial business remained commercially profitable.
Read all positive updates
Company Guidance
Management guided to both near‑term commercial stabilization and a fast, metric‑driven clinical cadence: commercially, Q2 net product revenue rose 11% sequentially to $105.8 million, the business remained commercially profitable, cash was $717.5 million at quarter‑end, operating expenses are expected to be broadly stable through the remainder of the year, they expect to stabilize product sales in H2 2026 and return to meaningful year‑over‑year growth in 2027 with a potential first U.S. product launch in 2028 (and targeted NRDL actions such as KarXT and VYVGART around 2027); clinically, they expect three registrational programs in SCLC and neuroendocrine carcinoma by year‑end 2026, Zoci’s global Phase III to complete enrollment in H1 2027 with a U.S. accelerated approval submission later in 2027 and approval anticipated in 2028, ~60 patients (median follow‑up ~8–9 months) to be presented at ESMO in October, dose exploration at 1.2 and 1.6 mg/kg with 1.6 mg/kg the planned RP2D, and a goal of materially improving on the current ~60–70% response/≈5‑month median PFS benchmark (targeting ~80% response and ~50% PFS improvement); immunology and earlier‑stage timelines include ZL‑1503 SAD/healthy‑volunteer PK/PD and ADA data in H2 2026 (biomarkers pSTAT6, TARC, CCL26), MAD AD data at a major conference next year, ZL‑6201 initial data in H1 2027, and an IND for ZL‑1311 by year‑end 2026, all underpinned by disciplined capital allocation and the claim that Zoci moved from IND to global pivotal in <2 years.Zai Lab Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 449.61M | 460.16M | 398.99M | 266.72M | 215.04M | 144.31M |
| Gross Profit | 253.90M | 269.07M | 251.13M | 170.90M | 141.02M | 92.07M |
| EBITDA | -168.80M | -158.25M | -234.57M | -365.11M | -434.84M | -689.46M |
| Net Income | -188.21M | -175.54M | -257.10M | -334.62M | -443.29M | -704.47M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 1.17B | 1.19B | 1.04B | 1.22B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 617.52M | 689.57M | 779.67M | 806.45M | 1.01B | 1.41B |
| Total Debt | 254.58M | 224.26M | 153.47M | 15.15M | 20.39M | 15.54M |
| Total Liabilities | 467.76M | 456.88M | 344.86M | 240.18M | 174.54M | 230.00M |
| Stockholders Equity | 607.04M | 715.50M | 840.90M | 796.12M | 1.05B | 1.38B |
Cash Flow | ||||||
| Free Cash Flow | -162.52M | -164.21M | -276.39M | -206.67M | -392.63M | -568.18M |
| Operating Cash Flow | -133.38M | -150.79M | -214.87M | -198.18M | -367.64M | -549.23M |
| Investing Cash Flow | -39.05M | 307.87M | -375.19M | -10.78M | 420.02M | 249.96M |
| Financing Cash Flow | 44.64M | 72.35M | 349.89M | -6.43M | -1.73M | 820.20M |
Zai Lab Technical Analysis
Positive
19.22
Price Trends
19.52
Positive
19.89
Positive
19.65
Positive
Market Momentum
1.66
Negative
77.49
Negative
90.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZLAB, the sentiment is Positive. The current price of 19.22 is below the 20-day moving average (MA) of 20.93, below the 50-day MA of 19.52, and below the 200-day MA of 19.65, indicating a bullish trend. The MACD of 1.66 indicates Negative momentum. The RSI at 77.49 is Negative, neither overbought nor oversold. The STOCH value of 90.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZLAB.
Zai Lab Risk Analysis
Zai Lab disclosed 101 risk factors in its most recent earnings report. Zai Lab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zai Lab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $2.19B | -14.32 | -49.73% | ― | 1083.56% | 30.89% | |
60 Neutral | $3.16B | -9.97 | -40.51% | ― | 34.52% | 41.20% | |
59 Neutral | $2.81B | -7.84 | -76.09% | ― | -58.40% | -31.99% | |
57 Neutral | $3.29B | -9.62 | -52.36% | ― | -97.27% | -44.90% | |
52 Neutral | $2.91B | -14.70 | -27.40% | ― | 5.13% | 17.00% | |
52 Neutral | $3.09B | -10.71 | -50.56% | ― | -100.00% | 18.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ZLAB
Zai Lab
25.90
-9.79
-27.43%
CLDX
Celldex
41.95
17.47
71.36%
IOVA
Iovance Biotherapeutics
6.98
4.48
179.20%
NRIX
Nurix Therapeutics
27.05
16.85
165.20%
NUVB
Nuvation Bio
6.22
3.32
114.48%
IMNM
Immunome
27.20
16.95
165.37%
Zai Lab Corporate Events
Business Operations and StrategyExecutive/Board ChangesStock BuybackShareholder Meetings
Zai Lab Shareholders Approve Directors, Auditors and Mandates
Positive
Jun 17, 2026
On June 17, 2026, Zai Lab Limited held its 2026 Annual General Meeting of Shareholders, with holders of more than one-tenth of its voting share capital present in person or by proxy. Shareholders approved the re-election of all nominated directors...
Business Operations and StrategyExecutive/Board Changes
Zai Lab Announces Leadership Change as COO Departs
Negative
May 22, 2026
On May 18, 2026, Zai Lab Limited’s board determined that President and Chief Operating Officer Josh Smiley would cease serving in those roles, with his last day at the company set for May 22, 2026. The operational responsibilities tied to hi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.